Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2024 Vol. 2 > No. 3 > 100086
Next Article Previous Article
EDITORIAL   Open Access     Cite

GLP-1R agonists: Full of hope, use with caution

  • 1.

    Frontier Innovation Center,Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Pathology of School of Basic Medical Sciences, Fudan University Shanghai, Shanghai 200032, China

  • 2.

    Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

More Information
  • Corresponding author: s-a-sally@163.com
  • Received Date:  January 22, 2024
    Accepted Date:  September 02, 2024
    Published Online:  September 03, 2024
The Innovation Medicine  2(3),  https://doi.org/10.59717/j.xinn-med.2024.100086  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Couzin-Frankel, J. (2023). Obesity meets its match. Science 382: 1226−1227. DOI: 10.1126/science.adn4691.

    View in Article CrossRef Google Scholar Scopus

    [2] Silva, S.C.A., de Lemos, M.D.T., Dos Santos Junior, O.H., et al. (2023). Overweight during development dysregulates cellular metabolism and critical genes that control food intake in the prefrontal cortex. Physiol. Behav. 276: 114453. DOI: 10.1016/j.physbeh.2023.114453.

    View in Article CrossRef Google Scholar Scopus

    [3] Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389: 2221−2232. DOI: 10.1056/NEJMoa2307563.

    View in Article CrossRef Google Scholar

    [4] Wang, L., Wang, W., Kaelber, D.C., et al. (2023). GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity. JAMA Oncol. 10: 256−258. DOI: 10.1001/jamaoncol.2023.5573.

    View in Article CrossRef Google Scholar

    [5] Sodhi, M., Rezaeianzadeh, R., Kezouh, A., et al. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330: 1795−1797. DOI: 10.1001/jama.2023.19574.

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Xu Y. and Li J. (2024). GLP-1R agonists: Full of hope, use with caution. The Innovation Medicine 2(3): 100086. https://doi.org/10.59717/j.xinn-med.2024.100086
    Xu Y. and Li J. (2024). GLP-1R agonists: Full of hope, use with caution. The Innovation Medicine 2(3): 100086. https://doi.org/10.59717/j.xinn-med.2024.100086

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(4590) PDF downloads(1368)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.